Results 101 to 110 of about 40,271 (232)

Analysis of Pharmacokinetic and Pharmacodynamic Interactions Between Chlorpromazine and Risperidone via Simultaneous Measurement of Multiple Receptor Occupancy in the Rat Brain

Biomedicines
Background/Objectives: Combination therapy for schizophrenia may exacerbate side effects mediated by multiple brain receptors. This study aimed to elucidate the pharmacodynamic and pharmacokinetic interactions between chlorpromazine and risperidone.
Gaku Akashita, Eriko Nakatani, Shimako Tanaka, Takashi Okura   +3 more
doaj   +1 more source

Elucidating the Role of SET as a Key Contributor to Neurodevelopmental Disability Within the 9q34.11 Deletion Syndrome Interval

Clinical Genetics, Volume 110, Issue 4, Page 438-448, October 2026.
This study reports a female proband with a de novo 9q34.11 deletion affecting SET, who underwent a 28‐year diagnostic odyssey after an atypical Rett syndrome clinical diagnosis. Genomic and proteomics analyses confirmed SET haploinsufficiency, refining the critical 9q34.11 region, and supporting speech therapy benefits in improving meaningful ...
Angelo Condell, Elaine Zhang, Tim Sikora, Sean Massey, Nicole J. Van Bergen, Min Wang, Cas Simons, Katrina M. Bell, Daniella H. Hock, David A. Stroud, David Francis, Wendy A. Gold, Martin B. Delatycki, John Christodoulou, Simranpreet Kaur   +14 more
wiley   +1 more source

Risperidone for children and adolescents with autism spectrum disorder: a systematic review

, 2018
Narong Maneeton,1 Benchalak Maneeton,1 Suwannee Putthisri,2 Pakapan Woottiluk,3 Assawin Narkpongphun,1 Manit Srisurapanont1 1Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2Department of Psychiatry, Faculty ...
Maneeton B, Putthisri S, Maneeton N, Woottiluk P, Narkpongphun A, Srisurapanont M   +5 more
core  

Use of monthly extended-release risperidone injection in schizophrenia: clinical experience

European Psychiatry
Introduction Monthly extended-release injectable risperidone is the new antipsychotic formulation of risperidone available in doses of 75 mg and 100 mg, approved for the treatment of schizophrenia.
E. de la Fuente Ruiz, M. D. C. Blasco Fresco, C. Álvarez Sanagustín, L. T. Durán Sandoval   +3 more
doaj   +1 more source

Prevalence of Psychotropic Use and Psychotropic Polypharmacy in a Finnish National Cohort of Persons With Intellectual Disabilities

Journal of Intellectual Disability Research, Volume 70, Issue 10, Page 1112-1124, October 2026.
ABSTRACT Background Psychotropic use and psychotropic polypharmacy are common in people with intellectual disabilities, but representative population‐based studies on this topic are scarce. We evaluated the prevalence of psychotropic use and psychotropic polypharmacy in a Finnish nationwide cohort of people with intellectual disabilities aged 0–97 ...
Ville Virtanen, Leena Saastamoinen, Maria Arvio, Hannu T. Vesala, Sonja Miettinen, Antti Teittinen, Anna‐Maija Tolppanen   +6 more
wiley   +1 more source

Multidisciplinary Oral Rehabilitation in Osteogenesis Imperfecta: 18‐Year‐Old Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder characterized by bone fragility and Type I collagen defects. Although dentinogenesis imperfecta (DI) is a classic manifestation, patients with OI may experience significant dental deterioration even in its absence due to inherent dentinal weakness.
Pegah Mosannen Mozafari, Mahsa Talafi Noghani, Iman Kashani, Reza Beyragh   +3 more
wiley   +1 more source

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

, 2013
Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan;
Ikeda M, Iwata N, Zhao Y, Kishi T
core  

Does Next Generation Sequencing (NGS)‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 731-744, September 2026.
CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained.
Jeanne Petit, Julien Plenecassagnes, Aurelie Brice, Florence Dalenc, Ludovic Mallet, Etienne Chatelut, Ayman Al Saati, Fabienne Thomas   +7 more
wiley   +1 more source

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
A case series studying outcomes up to 18 months in autistic patients from the UK Medical Cannabis Registry. ABSTRACT Introduction Autism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges.
Arushika Aggarwal, Simon Erridge, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva‐Mohan, Gabriel Shaya, James J. Rucker, Mikael H. Sodergren   +17 more
wiley   +1 more source

Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence

Neuropsychopharmacology Reports, Volume 46, Issue 3, September 2026.
Monitoring technologies integrated with artificial intelligence can enable personalized care, improved adherence, and reduced relapses among psychotic patients. ABSTRACT Background Nonadherence to antipsychotics affects nearly half of patients with schizophrenia, leading to rehospitalization, suicidality, and reduced quality of life.
Samuel Inshutiyimana, Kush Rajeshbhai Rana, Michael Matiop Aleu, Naomi Bwalya, Bonaventure Nsengimana, Onesmas Kipkurui   +5 more
wiley   +1 more source